EMEA CI on treatment, period & sequence effects [Regulatives / Guidelines]

posted by qwerty12 – Ireland, 2012-11-26 23:11 (4140 d 01:46 ago) – Posting: # 9594
Views: 3,384

In the most recent EMEA guideline it asks for the "tests for difference and the respective confidence intervals for the treatment effect, the period effect, and the sequence effect should be reported as descriptive data."

What exactly does this mean? How are they calculated? Can a SAS code be used to calculate the CIs on these effects.

I'm slightly confused as I thought that the confidence intervals for the difference in means between the two products to show bioequivalence would be the same as the CI for the treatment effect.


Thanks for your help in advance.

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
93 visitors (0 registered, 93 guests [including 11 identified bots]).
Forum time: 00:57 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5